The CD40–CD40 ligand (CD40L) interaction is key to the maturation of functional T and B cells. To inhibit this interaction in the context of autoimmunity, Karnell and colleagues generated a ...

The CD40–CD40L costimulatory pathway regulates adaptive and innate immune responses and has been implicated in the pathogenesis of multiple sclerosis. Frexalimab is a second-generation anti-CD40L ...

IRVINE, Calif.--(BUSINESS WIRE)-- Novus Therapeutics, Inc. (“Novus”) (NASDAQ: NVUS), a clinical stage biopharmaceutical company focused on developing life-changing, targeted medicines for patients ...

Predictors of Specialized Pediatric Palliative Care Involvement and Impact on Patterns of End-of-Life Care in Children With Cancer Three CD40L SNPs (rs3092920, rs3092952, rs3092936) were analyzed for ...

Please provide your email address to receive an email when new articles are posted on . Disease activity in relapsing MS patients significantly fell following treatment with frexalimab, a novel second ...

Frexalimab, an investigational second-generation CD40 ligand (CD40L) inhibitor, led to fewer new gadolinium-enhancing T1-weighted lesions in relapsing multiple sclerosis (MS), a phase II trial showed.

Bristol Myers Squibb has exercised its option to globally license Obsidian Therapeutics' CD40L-armed cell therapy. The deal gives Bristol Myers control of a drug designed to counter the ...

Topline results expected in the third quarter of 2024; planning a Phase 2 Trial for prevention of kidney transplant rejection Anti-CD40L has multiple possible indications in addition to solid organ ...

Predictors of Specialized Pediatric Palliative Care Involvement and Impact on Patterns of End-of-Life Care in Children With Cancer Endothelial vulnerability is a potential risk factor for ...